Prof. Zvi Fishelson

ביולוגיה תאית והתפתחותית אמריטוס
Prof. Zvi Fishelson
Phone: 03-6409620
Another phone: 03-6406038
Fax: 03-6407432
Office: Sackler School of Medicine, 422

Positions

Professor, Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University

Advisory Editor, Molecular Immunology

Associate Editor, Frontiers in  Immunity

 

Curriculum vitae

Research Associate, Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California 1980-June 1983.

Assistant member (Assistant Professor), Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California, July-September 1983.

Scientist, Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel, September 1983 - September 1985.

Scientist, Head of Complement Unit, R. Ben Ari Institute of Clinical Immunology, Kaplan Hospital, Rehovot, Israel, January 1984 -September 1985.

Senior Scientist, Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel, October 1985 - 1990.

Associate Professor, Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel, October 1990 - June 1992.

Visiting Scientist, MRC Immunochemistry Unit, Dept. of Biochemistry, University of Oxford, Oxford, U.K., June 1991- August 1992.

Associate Professor, Department of Cell Biology and Histology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, September 1992 - November 2003.

Visiting Scientist, Lab. Cell Biology, National Heart, Lung and Blood Institute, NIH, Bethesda, MD, U.S.A., Feb 1999 - Feb. 2000.

Chairman, Department of Cell and Developmental Biology (ex: Cell Biology and Histology), Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, Sept. 2001 - August 2005.

Full Professor, Department of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, from December 2003.

Tel Aviv University, Small Senate member, 2007-2008, 2012-2016.

Tel Aviv University, member of Board of Governors, 2014-2016.

 

Research

Molecular Analysis of Cancer Immunoresistance

The long-term goal of our research is to develop treatments for immune resistant cancers. In our research we explore the mechanism of complement-dependent cytotoxicity at the molecular level and the strategies used by cancer cells to resist cell death. Thus, we have identified the protective role of the stress proteins mortalin, hsp70 and hsp90, the protein kinases PKC and ERK and caveolin in cancer cells, enabling the cells to resist the damaging effects of the comlement membrane attack complex. Based on the novel findings, we are designing reagents that will sensitize cancer cells to cell death. The efficacy of the novel reagents is being examined in pre-clinical animal models of cancer.

 

Publications

 

Hillman Y., Mazkereth N., Farberov L., Shomron N. and Fishelson Z., Regulation of complement-dependent cytotoxicity by microRNAs miR-200b, miR-200c and miR-217, J. Immunol. 196: 5156-5165, 2016.

 

Mazkereth N., Rocca F., Schubert J.-R., Geisler C., Hillman Y., Egner A. and Fishelson Z., Complement triggers relocation of mortalin/GRP75 from mitochondria to the plasma membrane, Immunobiology, 221:1395-1406, 2016.

 

Jubran R, Kocsis J, Garam N, Maláti É, Gombos T, Barabás L, Gráf L, Prohászka Z, Fishelson Z., Circulating mitochondrial stress 70 protein/mortalin and cytosolic Hsp70 in blood: Risk indicators in colorectal cancer. Int. J. Cancer. 141: 2329-2335, 2017.

 

Rozenberg P., Ziporen L., Gancz D., Saar-Ray, M. and Fishelson Z., Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9. Cell death and Disease, 9, 150, 2018.

 

Lusthaus M., Mazkereth N., Donin N. and Fishelson Z., RIPK1, RIPK3 and MLKL are activated by sublytic complement and participate in complement-dependent cytotoxicity. Front. Immunology 9, 306, 2018.

 

Hillman Y, Mardamshina M, Pasmanik-Chor M, Ziporen L, Geiger T, Shomron N, Fishelson Z., MicroRNAs affect complement regulator expression and mitochondrial activity to modulate cell resistance to complement-dependent cytotoxicity. Cancer Immunol Res. 2019 Sep 19. pii: canimm.0818.2018. doi: 10.1158/2326-6066.CIR-18-0818. [Epub ahead of print].

 

Reviews

 

Kemper C., Pangburn M. K. and Fishelson Z. Complement Nomenclature 2014. Molec. Immunol. 61, 56-58, 2014.

 

Fishelson Z, Kirschfink M. Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention. Front Immunol. 2019 Apr 10;10:752. doi: 10.3389/fimmu.2019.00752. eCollection 2019.
Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel
UI/UX Basch_Interactive